1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Auro Laboratories Limited

Auro Laboratories Limited

AUROLAB.BO
Auro Laboratories LimitedIN flagBombay Stock Exchange
252.00
INR
-0.90
- -
1.57BMarket Cap

Total Valuation

Auro Laboratories Limited carries a market capitalization of 1.57B, placing it among publicly traded companies globally. Its enterprise value stands at 2.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.57B
Enterprise Value2.27B

Share Statistics

Auro Laboratories Limited currently has 6.23M shares outstanding.

Shares Outstanding6.23M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Auro Laboratories Limited trades at a trailing price-to-earnings ratio of 46.67. The price-to-sales ratio is 5.35, and the price-to-book ratio stands at 26.46.

PE Ratio46.67
PS Ratio5.35
PB Ratio26.46
P/TBV Ratio3.56
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Auro Laboratories Limited trades at an EV/EBITDA multiple of 32.48 and an EV/FCF ratio of 72.49. The EV/Sales ratio of 7.35 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.48 provides insight into valuation relative to core operating earnings.

EV / Sales7.35
EV / EBITDA32.48
EV / EBIT32.48
EV / FCF72.49

Financial Position

Auro Laboratories Limited maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 136.59, indicating elevated leverage, while an interest coverage ratio of 1.64 demonstrates limited ability to service its debt obligations.

Current Ratio1.08
Quick Ratio0.06
Debt / Equity136.59
Debt / EBITDA9.08
Interest Coverage1.64

Financial Efficiency

Auro Laboratories Limited posts a return on equity of 14.59 and a return on invested capital of 5.19.

Return on Equity (ROE)14.59
Return on Assets (ROA)3.21
Return on Invested Capital (ROIC)5.19
Return on Capital Employed (ROCE)8.50
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.70

Taxes

Over the trailing twelve months, Auro Laboratories Limited has paid 12.75M in income taxes, reflecting an effective tax rate of 26.52.

Income Tax12.75M
Effective Tax Rate26.52

Stock Price Statistics

Auro Laboratories Limited's stock has declined approximately -1.17647% over the past 52 weeks. The 50-day moving average sits at 259.88, while the 200-day moving average is 250.24.

Beta (5Y)N/A
52-Week Price Change-1.17647%
50-Day Moving Average259.88
200-Day Moving Average250.24
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Auro Laboratories Limited generated 308.36M in revenue and converted that into 35.33M in net income, yielding earnings per share of 5.68. EBITDA reached 69.74M, while operating income came in at 69.74M.

Revenue308.36M
Gross Profit248.06M
Operating Income69.74M
Pretax Income48.08M
Net Income35.33M
EBITDA69.74M
EBIT69.74M
Earnings Per Share (EPS)5.68

Balance Sheet

Auro Laboratories Limited holds 16.67M in cash and equivalents against 633.05M in total debt, resulting in a net debt position of 619.38M. Total book value stands at 62.33M, with working capital of 22.10M providing operational flexibility.

Cash & Cash Equivalents16.67M
Total Debt633.05M
Net Debt619.38M
Equity (Book Value)62.33M
Book Value Per Share10.02
Working Capital22.10M

Margins

Auro Laboratories Limited operates with a gross margin of 80.44, reflecting its pricing power and cost economics. The operating margin of 22.62 and net profit margin of 11.46 provide insight into operational efficiency.

Gross Margin80.44
Operating Margin22.62
Pretax Margin15.59
Profit Margin11.46
EBITDA Margin22.62

Scores

Auro Laboratories Limited posts an Altman Z-Score of 1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.79